Published Dr. Jatuporn Sujjitjoon, PhD, a researcher at the Molecular Medicine Research Center, Department of Research, and a key member of the Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), participated in the ESMO Immuno-Oncology Congress 2024 held in Geneva, Switzerland, from December 11th – 13th, 2024.
Dr. Sujjitjoon presented two impactful poster presentations:
- “Superior Antitumor Activities of Fourth-Generation CAR-T Cells Containing Three Costimulatory Domains Targeting GD2-Positive Tumors”
- “Potent Antitumor Efficiency of CD19-CAR T Cells Self-Secreting PD-L1 x CD3 BiTE Against Aggressive B-Cell Lymphoma”
Her contributions underscored advancements in CAR-T cell technologies and explored the development of multispecific immunotherapies for solid tumors.
The ESMO Immuno-Oncology Congress 2024 offered an advanced educational program and highlighted the latest scientific developments in this rapidly evolving field. Covering topics from the fundamentals of immunotherapies to cutting-edge research, treatment strategies, toxicity management, and data interpretation, the congress catered to oncology professionals dedicated to advancing cancer treatment through immunotherapy innovations.
